Dr. Reddys Laboratories is currently trading at Rs. 2819.90, up by 53.20 points or 1.92% from its previous closing of Rs 2766.70 on the BSE.
The scrip opened at Rs 2766.00 and has touched a high and low of Rs 2852.00 and Rs 2766.00 respectively. So far 44529 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs 2939.80 on 28-Feb-2014 and a 52 week low of Rs 2025.00 on 21-Aug-2013.
Last one week high and low of the scrip stood at Rs 2788.15 and Rs. 2662.05 respectively. The current market cap of the company is Rs 48034.48 crore.
The promoters holding in the company stood at 25.49% while Institutions and Non-Institutions held 40.73% and 15.32% respectively.
Dr Reddys Laboratories has reported results for first quarter ended June 30, 2014.
The company’s net profit jumped over 9 fold at Rs 602.75 crore as compared to Rs 64.86 crore for the quarter ended June 30, 2013. Its total income has increased by 50% to Rs 2782.36 crore for the quarter under review from Rs 1854.93 crore for the corresponding quarter of the previous year.
On the consolidated basis, the company has reported 52.49% rise in its net profit at Rs 550.39 crore for the quarter as compared to Rs 360.93 crore for the same quarter in the previous year. Total income has increased by 22.67% at Rs 3536.02 crore for quarter under review as compared to Rs 2882.48 crore for the quarter ended June 30, 2013.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1865.95 |
| Dr. Reddys Labs. | 1339.35 |
| Cipla | 1456.95 |
| Zydus Lifesciences | 1108.85 |
| Lupin | 2396.50 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: